It’s seldom that drug companies have the opportunity to develop a product that’s relevant to the entire world. In fact, it takes a global pandemic. IQVIA Institute for Human Data Science took on the task of estimating the financial impact of protecting the population from COVID-19, and the numbers are staggering. According to a recent FiercePharma article that discussed the figures, global vaccine sales will reach $157B by 2025. This estimate accounts for dramatic drops in the cost per dose going from an average of $22 per shot in 2021 to $9 per shot in 2023.
For its projections, IQVIA considered planned global manufacturing capacity, vaccinations to date, announced rollout strategies, and company contracts. This included 1.8 vaccine doses per person in 2021 and 2022, and shifted to 1.3 doses per person from 2023 to 2025 as more boosters and single-shot vaccinations will likely be available.
